Hyperperins A–X, fusicoccane diterpenoids including an unreported 5/7/5/3 tetracyclic carbon skeleton from Hypoestes purpurea and their T-type calcium channel inhibitory activity

i

This article has been updated. A Correction to this article was published on .

i

The Original Article was published on

i

The Original Article was published on

i

This article has been updated

i

This article was retracted on

i

This article has been updated

Abstract

Two unprecedented rearranged fusicoccane diterpenoids, hyperperins A (1) and B (2), and twenty-two new fusicoccane diterpenoids, hyperperins C–X (3–24), were isolated from the aerial parts of Hypoestes purpurea, as well as one known analog (25). The structures and absolute configurations of all newly isolated compounds were determined through comprehensive analyses, including NMR spectroscopy, HR-ESI-MS, electronic circular dichroism calculations, and single-crystal X-ray diffraction analysis. Structurally, compounds 1 and 2 were characterized by a previously unreported carbon skeleton featuring a 5/7/5/3 tetracyclic ring system. Compounds 19 and 20 represent the first examples of fusicoccane diterpenoids with epoxy groups at C-2/C-6 and C-6/C-7, respectively. A plausible biosynthesis pathway for compounds 1 and 2 was proposed. Additionally, compounds 1, 2, 3, 7, and 25 exhibited potent inhibitory activity against the Ca_v3.1 calcium channel with IC₅₀ values of 15.06 ± 1.19, 9.00 ± 1.04, 6.04 ± 0.67, 14.00 ± 1.20, and 6.26 ± 0.82 μmol·L⁻¹, respectively. These findings enrich the structural diversity of fusicoccane diterpenoids and provide promising lead compounds for the development of Ca_v3.1 calcium channel inhibitors.

Keywords

Hypoestes purpurea / Fusicoccane diterpenoids / Ca_v3.1 calcium channel inhibitory activities

CHANGE HISTORY

A Correction to this paper has been published:
https://doi.org

The Retraction Note was updated to reflect reception of statements of disagreement from all authors.

This article has been retracted.Please see the Retraction Notice for more detail:
https://doi.org

References

[1] Attali B, Gao ZB . Ion channels research in the post-genomic era. Acta Pharmacol Sin . 2016; 37(1):1-3. https://doi.org/10.1038/aps.2015.144.

[2] Behrends JC . Evolution of the ion channel concept: the historical perspective. Chem Rev . 2012; 112(12):6218-6226. https://doi.org/10.1021/cr300349g.

[3] Felix R, Corzo-Lopez A, Sandoval A . Voltage-gated ion channels in neuropathic pain signaling. Life. 2025; 15(6):888. https://doi.org/10.3390/life15060888.

[4] Fan JJ, Huang X . Ion channels in cancer: orchestrators of electrical signaling and cellular crosstalk. Rev Physiol Biochem Pharmacol. 2022; 183:103-133. https://doi.org/10.1007/112_2020_48.

[5] Cheng J, Wen J, Wang NX, et al. Ion channels and vascular diseases. Arterioscler Thromb Vasc Biol. 2019; 39(5):e146-e156. https://doi.org/10.1161/ATVBAHA.119.312004.

[6] Kumar P, Kumar D, Jha SK, et al. Ion channels in neurological disorders. Adv Protein Chem Struct Biol. 2016; 103:97-136. https://doi.org/10.1016/bs.apcsb.2015.10.006.

[7] Bagal SK, Brown AD, Cox PJ, et al. Ion channels as therapeutic targets: a drug discovery perspective. J Med Chem. 2013; 56(3):593-624. https://doi.org/10.1021/jm3011433.

[8] Santos R, Ursu O, Gaulton A, et al. A comprehensive map of molecular drug targets. Nat Rev Drug Discov. 2017; 16(1):19-34. https://doi.org/10.1038/nrd.2016.230.

[9] Bajaj S, Ong ST, Chandy KG . Contributions of natural products to ion channel pharmacology. Nat Prod Rep. 2020; 37(5):703-716. https://doi.org/10.1039/c9np00056a.

[10] Yunker AM, McEnery MW . Low-voltage-activated ("T-Type") calcium channels in review. J Bioenerg Biomembr. 2003; 35(6):533-575. https://doi.org/10.1023/b:jobb.0000008024.77488.48.

[11] Zamponi GW, Striessnig J, Koschak A, et al. The physiology, pathology, and pharmacology of voltage-gated calcium channels and their future therapeutic potential. Pharmacol Rev. 2015; 67(4):821-870. https://doi.org/10.1124/pr.114.009654.

[12] Perez-Reyes E. Molecular physiology of low-voltage-activated t-type calcium channels. Physiol Rev. 2003; 83(1):117-161. https://doi.org/10.1152/physrev.00018.2002.

[13] Melgari D, Frosio A, Calamaio S, et al. T-type calcium channels: a mixed blessing. Int J Mol Sci. 2022; 23(17):9894. https://doi.org/10.3390/ijms23179894.

[14] Powell KL, Cain SM, Snutch TP, et al. Low threshold T-type calcium channels as targets for novel epilepsy treatments. Br J Clin Pharmacol. 2014; 77(5):729-739. https://doi.org/10.1111/bcp.12205.

[15] Wang D, Ragnarsson L, Lewis RJ . T-type calcium channels in health and disease. Curr Med Chem. 2020; 27(19):3098-3122. https://doi.org/10.2174/0929867325666181001112821.

[16] Ono K, Iijima T . Cardiac T-type Ca²⁺ channels in the heart. J Mol Cell Cardiol. 2010; 48(1):65-70. https://doi.org/10.1016/j.yjmcc.2009.08.021.

[17] Weiss N, Zamponi GW . T-type calcium channels: from molecule to therapeutic opportunities. Int J Biochem Cell Biol. 2019; 108:34-39. https://doi.org/10.1016/j.biocel.2019.01.008.

[18] Yang YC, Tai CH, Pan MK, et al. The T-type calcium channel as a new therapeutic target for Parkinson’s disease. Pflugers Arch. 2014; 466(4):747-755. https://doi.org/10.1007/s00424-014-1466-6.

[19] Matthews LG, Puryear CB, Correia SS, et al. T-type calcium channels as therapeutic targets in essential tremor and Parkinson’s disease. Ann Clin Transl Neurol. 2023; 10(4):462-483. https://doi.org/10.1002/acn3.51735.

[20] Zhou FJ, Nian Y, Yan YM, et al. Two new classes of T-type calcium channel inhibitors with new chemical scaffolds from Ganoderma cochlear . Org Lett. 2015; 17(12):3082-3085. https://doi.org/10.1021/acs.orglett.5b01353.

[21] Ye YS, Li WY, Du SZ, et al. Congenetic hybrids derived from dearomatized isoprenylated acylphloroglucinol with opposite effects on Ca_v3.1 low voltage-gated Ca²⁺ Channel. J Med Chem. 2020; 63(4):1709-1716. https://doi.org/10.1021/acs.jmedchem.9b02056.

[22] Zhou HF, Li WY, Peng LY, et al. Rhynchines A-E: Ca_v3.1 calcium channel blockers from Uncaria rhynchophylla . Org Lett. 2021; 23(24):9463-9467. https://doi.org/10.1021/acs.orglett.1c03641.

[23] Editorial committee of flora of China, Chinese Academy of Sciences. Flora of China . Beijing: Science Pres, 2002.

[24] Shen CC, Ni CL, Huang YL, et al. Furanolabdane diterpenes from Hypoestes purpurea . J Nat Prod. 2004; 67(11):1947-1949. https://doi.org/10.1021/np0497402.

[25] D’Ambola M, Fiengo L, Chini MG, et al. Fusicoccane diterpenes from Hypoestes forsskaolii as heat shock protein 90 (Hsp90) modulators. J Nat Prod. 2019; 82(3):539-549. https://doi.org/10.1021/acs.jnatprod.8b00924.

[26] Yan T, Ding LF, Chen Y, et al. Labdane-type diterpenoids from Hypoestes phyllostachya inhibit pancreatic cancer stem cells. Phytochemistry. 2025; 240:114650. https://doi.org/10.1016/j.phytochem.2025.114650.

[27] Wu XD, Luo D, Tu WC, et al. Hypophyllins A−D, labdane-type diterpenoids with vasorelaxant activity from Hypoestes phyllostachya "Rosea". Org Lett. 2016; 18(24):6484-6487. https://doi.org/10.1021/acs.orglett.6b03388.

[28] Wu XD, Ding LF, Li WY, et al. Hypoestins A-D: highly modified fusicoccane diterpenoids with promising Ca_v3.1 calcium channel inhibitory activity from Hypoestes purpurea . Org Chem Front. 2022; 9(11):3075-3083. https://doi.org/10.1039/d2qo00265e.

[29] Rasoamiaranjanahary L, Marston A, Guilet D, et al. Antifungal diterpenes from Hypoestes serpens (Acanthaceae) . Phytochemistry. 2003; 62(3):333-337. https://doi.org/10.1016/s0031-9422(02)00551-4.

[30] Al Musayeib NM, Mothana RA, Mohamed GA, et al. Hypoestenonols A and B, new fusicoccane diterpenes from Hypoestes forskalei . Phytochem Lett. 2014; 10:23-27. https://doi.org/10.1016/j.phytol.2014.06.020.

[31] Cheng B, Ding LF, Yan T, et al. Hypofolins A-L, ent-labdane diterpenoids from the roots of Hypoestes phyllostachya 'Pink Splash'. Chem Biodivers. 2018; 15(6):e1800124. https://doi.org/10.1002/cbdv.201800124.

[32] Muhammad I, Mossa JS, Al-Yahya MA, et al. Hypoestenone: a fusicoccane diterpene ketone from Hypoestes forskalei . Phytochemistry. 1997; 44(1):125-129. https://doi.org/10.1016/S0031-9422(96)00474-8.

[33] Andriamihaja B, Martin MT, Rasoanaivo P, et al. A new diterpene from Hypoestes serpens . J Nat Prod. 2001; 64(2):217-218. https://doi.org/10.1021/np0001474.

[34] Al-Rehaily AJ, Al-Yahya MA, Mirza HH, et al. Verticillarone: a new seco-fusicoccane diterpenoid ketonepoxide from Hypoestes verticillaris . J Asian Nat Prod Res. 2002; 4(2):117-122. https://doi.org/10.1080/10286020290027399.

[35] Tang XW, Zhang F, Zeng T, et al. Enzymatic plasticity inspired by the diterpene cyclase CotB₂ . ACS Chem Biol. 2020; 15(10):2820-2832. https://doi.org/10.1021/acschembio.0c00645.

[36] Wang YL, Chen J, Zheng WS, et al. New diterpenoids from Euphorbia wallichii with antioxidant activity. Chin J Nat Med. 2025; 23(10):1248-1258. https://doi.org/10.1016/S1875-5364(25)60859-4.

[37] Zhang J, Yan JK, Dong HJ, et al. Dimeric sesquiterpenoids with anti-inflammatory activities from Inula britannica . Chin J Nat Med. 2025; 23(8):961-971. https://doi.org/10.1016/S1875-5364(25)60931-9.

[38] Cheng HZ, Liu H, Qi XY, et al. Anti-inflammatory and hepatoprotective triterpenoids from the traditional Mongolian medicine Gentianopsis barbata . Chin J Nat Med. 2025; 23(9):1111-1121. https://doi.org/10.1016/S1875-5364(25)60870-3.

[39] Gong Y, Liu R, Zha HJ, et al. Analgesic buxus alkaloids with enhanced selectivity for the low-voltage-gated calcium channel Ca_v3.2 over Ca_v3.1 through a new binding mode. Angew Chem Int Ed Engl. 2024; 63(1):e202313461. https://doi.org/10.1002/anie.202313461.

[40] Li M, Wang XJ, Zhao Q, et al. Bufalin-induced cardiotoxicity: new findings into mechanisms. Chin J Nat Med. 2020; 18(7):550-560. https://doi.org/10.1016/S1875-5364(20)30065-0.